GlassScriptPhysician profile
Nathaniel J Casey
NPI 1104523224
$559.32
in general payments reported to CMS, 2019-2025
16 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $94.78 · 2024: $188 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $90.71 | 2023-2024 | Jardiance, Emgality, Zepbound |
| Abbvie INC. | $87.83 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $73.17 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $67.64 | 2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $46.85 | 2023-2024 | Fasenra |
| Genzyme Corporation | $25.47 | 2025 | |
| Apellis Pharmaceuticals, INC. | $21.83 | 2025 | Empaveli |
| Amgen INC. | $21.81 | 2025 | Tavneos |
| Travere Therapeutics, INC. | $18.17 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.14 | 2023 | Tradjenta |
| Glaxosmithkline, LLC. | $16.04 | 2025 | Penmenvy |
| Sumitomo Pharma America, INC. | $15.84 | 2024 | Gemtesa |
| Janssen Pharmaceuticals, INC | $15.12 | 2024 | Xarelto |
| Corcept Therapeutics | $14.92 | 2025 | Korlym |
| Pfizer INC. | $14.46 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $13.32 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Casey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.